Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

Rhea-AI Summary

Tevogen Bio (Nasdaq: TVGN) announced it will host two panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2025. The first panel, 'AI In Biopharma: Next Frontier of Medical Innovation', will explore how AI technologies can revolutionize drug discovery, accelerate development, and reduce costs. The second panel, 'Pioneering the Economics of Health: Balancing Access and Outcomes', will examine healthcare ecosystem interdependencies.

Notable panelists include Microsoft's Global Chief Medical Officer David Rhew, Rubix Health's Sean Tunis, Simon-Kucher's Peter Ehrhardt, and former VA Acting Under Secretary Poonam Alaigh. The event will be held at the Marines' Memorial Club & Hotel, featuring panel discussions from 2:00 PM to 4:00 PM PST, followed by a reception.

Positive

• Participation in major healthcare investment symposium enhances company visibility
• Strategic focus on AI implementation in biopharma operations
• High-profile panel participants from Microsoft, VA, and other major institutions

Negative

• None.

• The JPM Healthcare Conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
• Pioneering the Economics of Health to examine the interdependencies of the healthcare ecosystem which are often overlooked when only considering a singular silo of it.
• AI In Biopharma to highlight how AI-driven technologies can revolutionize drug discovery, accelerate development timelines, enhance patient accessibility, foster quicker innovation, and significantly reduce operating costs.
• Panelists to include David Rhew (Global Chief Medical Officer and VP of Healthcare, Microsoft), Sean Tunis (Principal, Rubix Health), Peter Ehrhardt (Senior Partner, Simon-Kucher), and Poonam Alaigh (Former Acting Under Secretary for Health, U.S. Department of Veterans Affairs).

WARREN, N.J., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), will host panel discussions at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Event Details

Date:
Monday, January 13, 2025

Location:
Marines' Memorial Club & Hotel, 609 Sutter St., San Francisco, CA 94102

Time (PST):
2:00 PM – 2:30 PM – AI in Biopharma: Next Frontier of Medical Innovation
Panelists:
Dr. David Rhew – Global Chief Medical Officer and VP of Healthcare, Microsoft (Nasdaq: MSFT)
Dr. Sean Tunis – Principal, Rubix Health
Mittul Mehta – Chief Information Officer and Head of Tevogen.AI, Tevogen Bio

2:30 pm – 3:15 pm – Afternoon Coffee Break

3:15 PM – 4:00 PM – Pioneering the Economics of Health: Balancing Access and Outcomes
Victor Sordillo – MD, Risk Advisory Services, Verita CSG, Inc; Member, Board of Directors, Tevogen Bio
Peter Ehrhardt – Senior Partner at Simon-Kucher & Partners
Dr. Poonam Alaigh – Former Acting Under Secretary for Health, U.S. Department of Veterans Affairs; Former Commissioner, New Jersey Department of Health
Dr. Sean Tunis - Principal, Rubix Health; Senior Fellow, Tufts Center for Evaluation of Value and Risk in Health; Venture Mentor, Johns Hopkins Tech Ventures
Dr. Ryan Saadi – Founder and CEO, Tevogen Bio

4:00 PM – 6:00 PM – Reception and Cocktails

For inquiries regarding additional event details, please contact communications@tevogen.com.

About Tevogen Bio

Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.

Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com

FAQ

When and where will Tevogen Bio (TVGN) host its panels at the JP Morgan Healthcare Conference 2025?

Tevogen Bio will host its panels on Monday, January 13, 2025, at the Marines' Memorial Club & Hotel in San Francisco, California.

What are the main topics of Tevogen Bio's (TVGN) panel discussions at JPM 2025?

The two main topics are 'AI In Biopharma: Next Frontier of Medical Innovation' and 'Pioneering the Economics of Health: Balancing Access and Outcomes'.

Who are the key speakers at Tevogen Bio's (TVGN) JPM 2025 panels?

Key speakers include David Rhew (Microsoft), Sean Tunis (Rubix Health), Peter Ehrhardt (Simon-Kucher), and Poonam Alaigh (Former VA Under Secretary).

What AI benefits will be discussed at Tevogen Bio's (TVGN) JPM panel?

The panel will discuss how AI can revolutionize drug discovery, accelerate development timelines, enhance patient accessibility, foster innovation, and reduce operating costs.